Semaglutide – Mechanism of Action and Use

Semaglutide constitutes a synthetic analogue of the naturally occurring human glucagon-like peptide-1 (GLP-1) hormone, exerting its pharmacological effects through selective activation of GLP-1 receptors, thereby initiating a cascade of metabolic responses. Endogenous GLP-1 is primarily secreted by enteroendocrine cells located in the small intestine, with its synthesis markedly amplified following the ingestion of meals rich in fats and carbohydrates. The principal therapeutic action involves the stimulation of pancreatic beta cells to enhance insulin secretion—a hormone responsible for lowering blood glucose concentrations. Concurrently, semaglutide suppresses the release of glucagon (a counterregulatory hormone that elevates glycemia) from pancreatic alpha cells. A critical feature of this mechanism is its glucose-dependent nature: during hypoglycemic episodes (low blood sugar), insulin secretion is automatically attenuated, preventing dangerous declines in glycemia. Additionally, through central actions on satiety centers within the hypothalamus, semaglutide exerts an anorectic effect—diminishing appetite and reducing overall caloric intake, thereby positioning it as a promising adjunct therapy for weight loss in individuals with obesity or overweight conditions.

During the current year, the U.S. Food and Drug Administration (FDA) approved the therapeutic administration of semaglutide via subcutaneous injection at a target dosage of 2.4 milligrams per week. The indication encompasses adult patients whose body mass index (BMI) meets or exceeds 27 kg/m² and who present with concomitant metabolic risk factors—including diagnosed type 2 diabetes mellitus, elevated blood cholesterol levels, or arterial hypertension. Alternatively, the medication may also be prescribed to individuals with a BMI of at least 30 kg/m², even in the absence of comorbid conditions. According to clinical guidelines, optimal therapeutic outcomes are achieved through the integration of pharmacotherapy with a personalized, hypocaloric dietary regimen and a progressively intensified physical activity program. The escalating prevalence of overweight and obesity represents one of the foremost challenges in contemporary preventive medicine, given its strong association with the development of non-communicable diseases that dominate mortality statistics in the United States—and, as notably emphasized, in Poland as well, where such conditions account for a substantial proportion of premature deaths.

The STEP clinical trial initiative was designed to rigorously assess both the efficacy and safety profile of semaglutide administered at doses exceeding those conventionally approved for type 2 diabetes management. A primary investigative focus within this program involved the comprehensive tracking of body composition alterations among participants. To date, complete findings from four of the six planned clinical investigations have been disseminated, yielding substantial evidence pertaining to both metabolic indicators and anthropometric measurements.

This clinical investigation enrolled a total of 1,961 adult participants classified as either overweight or obese, all of whom presented with concomitant comorbidities but were explicitly excluded if diagnosed with diabetes. Subjects were randomly allocated into two parallel treatment arms: the first cohort received once-weekly subcutaneous injections of semaglutide at a fixed 2.4-milligram dose throughout the trial duration, whereas the second cohort was administered a visually identical placebo under the same injection protocol. Concurrently, both groups underwent structured lifestyle modification programs, integrating tailored dietary guidance alongside progressive physical activity recommendations.

Following a 68-week observation period, the collected data revealed statistically significant disparities between the two arms. Participants in the semaglutide group achieved a mean body weight reduction of 14.9% relative to baseline measurements, in stark contrast to the placebo group’s modest 2.4% decrease. Furthermore, over half (52.3%) of the semaglutide-treated individuals succeeded in losing ≥15% of their initial body weight—a threshold surpassed by merely 4.8% of placebo recipients. These findings robustly demonstrate the superior efficacy of semaglutide-based pharmacotherapy in facilitating clinically meaningful weight loss outcomes.

Within the scope of the subsequent clinical investigation, participants characterized by excess body weight alongside a concurrent diagnosis of diabetes were enrolled in a 68-week intervention protocol. The study population was stratified into three distinct cohorts: the first was administered semaglutide at a dosage of 1 milligram, the second received an elevated dose of 2.4 milligrams of the same pharmaceutical agent, and the third was given a pharmacologically inactive substance serving as a placebo.

Subsequent analysis of the collected data revealed that the most substantial reduction in body mass occurred within the cohort utilizing the higher concentration of the medication—where the mean weight loss amounted to 9.64% of baseline body weight. Conversely, the placebo group exhibited the least favorable outcomes, with an average weight reduction of merely 3.42%. Participants treated with 1 milligram of semaglutide achieved an intermediate result, experiencing a mean loss of 6.99% of their initial body weight.

During the third phase of clinical investigations, participants included individuals classified as overweight or obese, all of whom presented with concomitant metabolic or systemic conditions but without a confirmed diagnosis of diabetes mellitus. Each subject was enrolled in a comprehensive psychological support framework designed to facilitate the adoption of sustainable lifestyle modifications—encompassing dietary patterns, physical activity regimens, and stress-management techniques. Furthermore, participants were randomly assigned to one of two intervention cohorts: one group received the active pharmacological agent semaglutide, while the other was administered an indistinguishable placebo formulation with identical dosing protocols.

Following a 68-week observation period marked by continuous health parameter monitoring, statistically significant disparities in weight reduction outcomes emerged between the two groups. Among those treated with semaglutide, the mean body weight loss reached 16.0% of baseline measurements, whereas the placebo cohort exhibited an average reduction of 5.7%. These findings suggest a potentially superior efficacy of the combined pharmacological-behavioral intervention compared to behavioral modification alone in achieving long-term weight management among patients with obesity and comorbid conditions.

Within the randomized STEP 4 clinical investigation, all enrolled participants underwent a twenty-week initial phase during which they were administered a standardized 2.4-milligram dose of the anti-obesity agent semaglutide. Subsequently, over the ensuing forty-eight-week period, one cohort persisted with uninterrupted semaglutide administration, whereas the comparative cohort was transitioned to a pharmacologically inert placebo formulation. Data analysis revealed that individuals within the placebo-assigned group experienced an average body weight increase approaching seven percent of baseline measurements between the twentieth and sixty-eighth weeks of observation. Conversely, those who maintained continuous semaglutide therapy demonstrated sustained, statistically significant weight reduction. It remains indeterminate, however, what the long-term ramifications of prolonged semaglutide use may entail, nor is the rate of weight regain following treatment cessation fully characterized. Furthermore, the actively treated cohort exhibited a spectrum of adverse physiological responses, with diarrheal episodes and persistent nausea reported as the most prevalent. The full catalog of potential adverse effects extends well beyond these observations, necessitating additional comprehensive safety evaluations of this pharmacotherapeutic intervention.

As with any pharmacological agent, semaglutide carries the potential to induce a spectrum of adverse reactions, which may include persistent nausea, recurrent vomiting, dysregulated bowel movements (manifesting as either diarrhea or constipation), abdominal discomfort of varying severity, cephalalgia, chronic fatigue syndrome-like exhaustion, vertiginous episodes, and hypoglycemic incidents in individuals with preexisting diabetes mellitus. Additional documented effects encompass abdominal distension, inflammatory conditions of the intestinal mucosa, and symptoms consistent with gastroesophageal reflux disease. Owing to the elevated likelihood of gastrointestinal disturbances, clinical guidelines advocate initiating treatment with a substantially reduced dose relative to the intended therapeutic target, followed by a gradual titration phase. It is critical to note that the safety profile of the drug remains unclear in patients with a history of pancreatic inflammation. Product labeling further highlights a potential association between semaglutide administration and an increased incidence of thyroid neoplasms—a correlation substantiated in preclinical rodent models (particularly in rats). Furthermore, emerging evidence suggests a possible elevation in the risk of acute pancreatitis, cholelithiasis, and progressive renal insufficiency. Psychiatric manifestations, including mood disorders, major depressive episodes, and suicidal ideation, have also been reported, necessitating heightened vigilance during patient monitoring.

Semaglutide is categorically contraindicated in patients with a personal or familial history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN-2), a hereditary syndrome characterized by the co-occurrence of medullary thyroid cancer alongside an elevated risk of developing pheochromocytoma (adrenal gland tumors) and primary hyperparathyroidism. Consistent with standard pharmacological precautions, semaglutide must not be administered to individuals with documented hypersensitivity to the active molecule or any of the excipients contained in the formulation. Additional absolute contraindications include pregnancy and lactation due to potential teratogenic or neonatal risks that have not been definitively excluded. While semaglutide demonstrates substantial efficacy in facilitating weight loss—particularly in patients with class III obesity or concurrent type 2 diabetes—its mechanism of action does not obviate the necessity for sustained lifestyle modifications. Optimal therapeutic outcomes are achievable only through the integration of pharmacotherapy with a structured, hypocaloric nutritional plan and individualized physical activity regimens tailored to the patient’s functional capacity. It is critical to note that discontinuation of semaglutide is associated with a high likelihood of weight regain, often exceeding the patient’s baseline weight. In Poland, the drug is currently approved solely for the management of diabetes mellitus, and its potential off-label use for obesity treatment remains outside the scope of authorized indications.